CARDIAC · Injectable
VIP + MOTS-c Blend.
Neuroprotective + mitochondrial stack
How it works
Class & mechanism.
Class
Neuroprotective & Mitochondrial Metabolic Blend
Mechanism
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide that acts via VPAC1/VPAC2 receptors to elevate intracellular cAMP, modulate dendritic cells and T-regulatory cells, block peripheral innate immune activation, lower pulmonary artery pressure, and promote astroglia-mediated neuroprotection against excitotoxicity and amyloid toxicity. MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded directly within mitochondrial DNA that translocates to the nucleus under metabolic stress, activating AMPK and the NUPR1-HMOX1 pathway to restore metabolic homeostasis. Together, VIP provides systemic anti-inflammatory and neuroprotective signaling while MOTS-c optimizes mitochondrial bioenergetics and insulin sensitivity — a complementary axis targeting both neural protection and cellular energy metabolism.
Did you know
MOTS-c is the only known peptide encoded in mitochondrial DNA — not nuclear DNA — meaning your mitochondria have their own dedicated anti-aging hormone system that's completely separate from your genome, and it declines with age just like testosterone does.
Benefits
What it does.
Neuroprotection against beta-amyloid toxicity and neuroinflammation via VIP-stimulated astroglia signaling
Enhanced insulin sensitivity and glucose metabolism through MOTS-c activation of AMPK pathway in skeletal muscle
Reduced systemic and neurological inflammation through VIP modulation of Th17/Treg balance and IL-10 upregulation
Improved metabolic flexibility and mitochondrial biogenesis via MOTS-c's AMPK-driven energy sensing
Support for cardiovascular regulation: VIP lowers pulmonary artery systolic pressure; MOTS-c protects against pressure overload-induced cardiac hypertrophy
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
VIP nasal spray (replacement doses) in 20 patients with chronic inflammatory response syndrome safely reduced refractory symptoms, corrected inflammatory markers, raised VIP and MSH levels, and reduced pulmonary artery systolic pressure during exercise to normal within 2 months — durable response at 18-month follow-up
SOURCE · Scientific Research Publishing (SciRP) — Shoemaker et al., open-label trial in CIRS-WDB patients
MOTS-c treatment improved cardiac function in diabetic rats by enhancing glucose metabolism via NRG1-ErbB signaling, upregulating antioxidant defences, and restoring mitochondrial bioenergetic function in diabetic hearts
SOURCE · Frontiers in Endocrinology (2022); Frontiers in Physiology (2025) — Li et al. and associated Khavinson-era studies
Circulating MOTS-c levels in young people are 11–21% higher than in middle- and old-aged individuals, and systemic MOTS-c injection in aged mice reversed age-related skeletal muscle insulin resistance and restored MOTS-c to youthful levels
SOURCE · PMC / Frontiers in Endocrinology (2023) — 'MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation'
Protocol
How to use it.
Dosing
VIP: 3–6 units (100–200 mcg) intranasally, 1–2 times daily (standard research protocol). MOTS-c: 5–10 mg subcutaneously, 3–5 times per week. Blend protocols vary; both components are typically administered on the same days.
Cycle
VIP: 30-day treatment periods; reassess response and inflammatory markers before continuing. MOTS-c: 8–12 week cycles; endogenous levels are measured at baseline and post-cycle in research settings. Allow 4–6 weeks between cycles.
Contraindications
When to skip it.
VIP: Caution in patients with low blood pressure (vasodilatory effects). Intranasal route avoids systemic injection risks. MOTS-c may interact with drugs targeting AMPK (e.g., metformin — additive effect). Persistent injection site reactions reported with MOTS-c analog CB4211 in Phase I trials. Neither compound is FDA-approved. Avoid in pregnancy. Physician oversight required.
Always cleared with your concierge before protocol start.
Pricing
What it costs.
Indicative range for VIP + MOTS-c Blend, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See VIP + MOTS-c Blend pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $150–$226 USD